Type 1 diabetes (T1D) is one of the most common chronic diseases of childhood. It is prompted by the autoimmune destruction of insulin-producing beta cells in pancreatic islets and leaves affected individuals dependent on daily insulin injections. At present T1D treatment is done by lifelong delivery of novel kinds of insulin which have been synthesized recently. Numerous approaches have attempted to prevent or stop islet cell destruction on the basis of immunotherapies to block T cell responses against β cells antigens which are quite common at the time of initiation as well as development of T1D.
(2022). Development of Novel Antibody-Based Approach for T1D. Egyptian Society of Diabetes and Lipidology Journal, 2(1), -. doi: 10.21608/esdlj.2022.455707
MLA
. "Development of Novel Antibody-Based Approach for T1D", Egyptian Society of Diabetes and Lipidology Journal, 2, 1, 2022, -. doi: 10.21608/esdlj.2022.455707
HARVARD
(2022). 'Development of Novel Antibody-Based Approach for T1D', Egyptian Society of Diabetes and Lipidology Journal, 2(1), pp. -. doi: 10.21608/esdlj.2022.455707
VANCOUVER
Development of Novel Antibody-Based Approach for T1D. Egyptian Society of Diabetes and Lipidology Journal, 2022; 2(1): -. doi: 10.21608/esdlj.2022.455707
)
